Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (SONNET)
This study has been terminated.
( Study placed on Clinical Hold )
Study NCT01199731   Information provided by ViiV Healthcare

First Received on September 9, 2010.   Last Updated on April 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
More general conditions related to this trial
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
GSK2248761 100 mg once daily
GSK2248761 200 mg once daily
Etravirine
Additional drug interventions recognized in this trial
Reverse Transcriptase Inhibitors
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
ViiV Healthcare
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services